Pletal Related Published Studies
Well-designed clinical trials related to Pletal (Cilostazol)
Efficacy of cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: a meta-analysis of randomised controlled trials. [2009.08]
Combined aspirin and cilostazol treatment is associated with reduced platelet aggregation and prevention of exercise-induced platelet activation. [2009.05]
Effect of cilostazol treatment on adiponectin and soluble CD40 ligand levels in diabetic patients with peripheral arterial occlusion disease. [2009.05]
The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease. [2009.05]
Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study. [2009.04]
The vascular and biochemical effects of cilostazol in diabetic patients with peripheral arterial disease. [2009.04]
Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study. [2009.03.31]
The effects of cilostazol on exercise-induced ischaemia-reperfusion injury in patients with peripheral arterial disease. [2009.03]
The Vascular and Biochemical Effects of Cilostazol in Diabetic Patients With Peripheral Arterial Disease. [2009.01.11]
Efficacy of cilostazol after endovascular therapy for femoropopliteal artery disease in patients with intermittent claudication. [2009.01.06]
The effects of cilostazol on peripheral neuropathy in diabetic patients with peripheral arterial disease. [2008.12]
Inhibition of platelet aggregation by combined therapy with aspirin and cilostazol after off-pump coronary artery bypass surgery. [2008.08]
Protective Effects of Cilostazol against Transient Focal Cerebral ischemia and Chronic Cerebral Hypoperfusion Injury. [2008.06]
Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects). [2008.02]
Antiplatelet cilostazol is beneficial in diabetic and/or hypertensive ischemic stroke patients. Subgroup analysis of the cilostazol stroke prevention study. [2008]
Effects of triple antiplatelet therapy (aspirin, clopidogrel, and cilostazol) on platelet aggregation and P-selectin expression in patients undergoing coronary artery stent implantation. [2007.08.15]
Cilostazol reduces inflammatory burden and oxidative stress in hypertensive type 2 diabetes mellitus patients. [2007.08]
Cilostazol reduces inflammatory burden and oxidative stress in hypertensive type 2 diabetes mellitus patients. [2007.05.03]
The effect of supervised exercise and cilostazol on coagulation and fibrinolysis in intermittent claudication: a randomized controlled trial. [2007.01]
Reduced 6-month resource use and costs associated with cilostazol in patients after successful coronary stent implantation: results from the Cilostazol for RESTenosis (CREST) trial. [2006.10]
A prospective randomized antiplatelet trial of cilostazol versus clopidogrel in patients with bare metal stent. [2006.03.05]
Effects of angiotensin-converting enzyme inhibitors or an angiotensin receptor blocker in combination with aspirin and cilostazol on in-stent restenosis. [2006.03]
Cilostazol in secondary prevention of stroke: impact of the Cilostazol Stroke Prevention Study. [2005.12.15]
Cilostazol in secondary prevention of stroke: Impact of the Cilostazol Stroke Prevention Study. [2005.11.03]
Coronary stent restenosis in patients treated with cilostazol. [2005.11.01]
RACTS: a prospective randomized antiplatelet trial of cilostazol versus ticlopidine in patients undergoing coronary stenting: long-term clinical and angiographic outcome. [2005.08]
Randomized comparison of cilostazol vs ticlopidine for antiplatelet therapy after coronary stenting. [2005.07]
Comparison of cilostazol and clopidogrel after successful coronary stenting. [2005.04.01]
Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis. [2005.04]
Comparative inhibitory effects of cilostazol and ticlopidine on subacute stent thrombosis and platelet function in acute myocardial infarction patients with percutaneous coronary intervention. [2005.01]
Effect of cilostazol, a phosphodiesterase inhibitor, on carotid IMT in Japanese type 2 diabetic patients. [2004.12]
Cilostazol, clopidogrel or ticlopidine to prevent sub-acute stent thrombosis: a meta-analysis of randomized trials. [2004.12]
The phosphodiesterase 3 inhibitor cilostazol dilates large cerebral arteries in humans without affecting regional cerebral blood flow. [2004.12]
Cilostazol inhibits leukocyte integrin Mac-1, leading to a potential reduction in restenosis after coronary stent implantation. [2004.10.06]
Effects of antiplatelet agents on subacute thrombosis and restenosis after successful coronary stenting: a randomized comparison of ticlopidine and cilostazol. [2004.07]
Comparison of cilostazol and ticlopidine for one-month effectiveness and safety after elective coronary stenting. [2004.05]
Methods for the economic and quality of life supplement to the cilostazol for RESTenosis (CREST) trial. [2004.05]
Effects of cilostazol in patients with Raynaud's syndrome. [2003.12.01]
Effect of cilostazol on vasomotor reactivity in patients with vasospastic angina pectoris. [2003.07.01]
Cilostazol: a review of its use in intermittent claudication. [2003]
Failure of pentoxifylline or cilostazol to improve blood and plasma viscosity, fibrinogen, and erythrocyte deformability in claudication. [2002.09]
Randomized comparison of cilostazol versus ticlopidine hydrochloride for antiplatelet therapy after coronary stent implantation for prevention of late restenosis. [2002.08]
Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study. [2002.03]
A phosphodiesterase inhibitor, cilostazol, prevents the onset of silent brain infarction in Japanese subjects with Type II diabetes. [2002.02]
Cilostazol treatment of claudication in diabetic patients. [2002]
Differential lipogenic effects of cilostazol and pentoxifylline in patients with intermittent claudication: potential role for interleukin-6. [2001.10]
Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication. [2001.09]
Decrease in carotid intima media thickness after 1 year of cilostazol treatment in patients with type 2 diabetes mellitus. [2001.04]
Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake. [2001.01]
Comparison of ticlopidine and cilostazol for the prevention of restenosis after percutaneous transluminal coronary angioplasty. [2001.01]
Cilostazol: treatment of intermittent claudication. [2001.01]
Effects of cilostazol on late lumen loss and repeat revascularization after Palmaz-Schatz coronary stent implantation. [2001.01]
Effects of cilostazol on resting ankle pressures and exercise-induced ischemia in patients with intermittent claudication. [2001]
A comparison of cilostazol and pentoxifylline for treating intermittent claudication. [2000.11]
Effects of cilostazol on angiographic restenosis after coronary stent placement. [2000.09.01]
Increased platelet aggregability in response to shear stress in acute myocardial infarction and its inhibition by combined therapy with aspirin and cilostazol after coronary intervention. [2000.05.01]
Usefulness of cilostazol versus ticlopidine in coronary artery stenting. [1999.12.15]
Impact of cilostazol on clinical and angiographic outcome after primary stenting for acute myocardial infarction. [1999.11.01]
Comparison of cilostazol versus ticlopidine therapy after stent implantation. [1999.09.01]
Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty. [1999.07.06]
Effect of cilostazol on the pharmacokinetics and pharmacodynamics of warfarin. [1999]
Inhibition of CYP2D6 by quinidine and its effects on the metabolism of cilostazol. [1999]
Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. [1998.12]
Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. [1998.08.18]
Effects of cilostazol on late lumen loss after Palmaz-Schatz stent implantation. [1998.08]
Effects of probucol and cilostazol alone and in combination on frequency of poststenting restenosis. [1998.07.15]
Impact of cilostazol on intimal proliferation after directional coronary atherectomy. [1998.03]
Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. [1998.02]
Comparison of cilostazol with warfarin as antithrombotic therapy after femoro-popliteal bypass surgery using an ePTFE graft. [1997.11]
A randomized trial of aspirin versus cilostazol therapy after successful coronary stent implantation. [1997.09]
Effect of cilostazol, a novel anti-platelet drug, on restenosis after percutaneous transluminal coronary angioplasty. [1996.04]
Bronchodilator and bronchoprotective effects of cilostazol in humans in vivo. [1995.01]
Well-designed clinical trials possibly related to Pletal (Cilostazol)
Relation of genetic polymorphisms in the cytochrome P450 gene with clopidogrel resistance after drug-eluting stent implantation in Koreans. [2009.07.01]
Therapeutic effects of modified Danggui Sini Decoction on plasma level of advanced glycation end products in patients with Wagner grade 0 diabetic foot: a randomized controlled trial. [2009.07]
Type 3 phosphodiesterase inhibitors may be protective against cerebrovascular events in patients with claudication. [2008.05]
Medical treatment of peripheral arterial disease. [2006.02.01]
Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study. [2004.08.31]
Interventions to prevent aspiration pneumonia in older adults: a systematic review. [2003.07]
A paclitaxel-eluting stent for the prevention of coronary restenosis. [2003.04.17]
Current medical therapies for patients with peripheral arterial disease: a critical review. [2002.01]
A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. [1999.09.27]
The effect of withdrawal of drugs treating intermittent claudication. [1999.08]
Other research related to Pletal (Cilostazol)
Early combined treatment with cilostazol and bone marrow-derived endothelial progenitor cells markedly attenuates pulmonary arterial hypertension in rats. [2009.09]
Cilostazol reduces proliferation through c-Myc down-regulation in MDCK cells. [2009.08.15]
Ginkgo biloba extract enhances antiplatelet and antithrombotic effects of cilostazol without prolongation of bleeding time. [2009.07]
Combination treatment with normobaric hyperoxia and cilostazol protects mice against focal cerebral ischemia-induced neuronal damage better than each treatment alone. [2009.07]
Cilostazol may prevent cerebral vasospasm following subarachnoid hemorrhage. [2009.06]
Selective phosphodiesterase-3 inhibitor cilostazol ameliorates experimental autoimmune encephalomyelitis. [2009.05.06]
Cilostazol ameliorates metabolic abnormalities with suppression of proinflammatory markers in a db/db mouse model of type 2 diabetes via activation of peroxisome proliferator-activated receptor gamma transcription. [2009.05]
Cilostazol and pentoxifylline decrease angiogenesis, inflammation, and fibrosis in sponge-induced intraperitoneal adhesion in mice. [2009.04.10]
Cilostazol protects against hemorrhagic transformation in mice transient focal cerebral ischemia-induced brain damage. [2009.03.13]
Multifaceted effects of selective inhibitor of phosphodiesterase III, cilostazol, for cerebral vasospasm after subarachnoid hemorrhage in a dog model. [2009]
The Effects of Cilostazol on Exercise-induced Ischaemia-reperfusion Injury in Patients with Peripheral Arterial Disease. [2008.12.26]
Evaluation of the antiplatelet effects of cilostazol, a phosphodiesterase 3 inhibitor, by VASP phosphorylation and platelet aggregation. [2008.11]
Effects of cilostazol and pentoxifylline on forearm reactive hyperemia response, lipid profile, oxidative stress, and inflammatory markers in patients with intermittent claudication. [2008.10]
Cilostazol and peripheral arterial disease. [2008.10]
A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. [2008.09]
An oral administration of cilostazol before focal ischemia reduces the infarct volume with delayed cerebral blood flow increase in rats. [2008.09]
Antiplatelet agents sarpogrelate and cilostazol affect experimentally-induced ventricular arrhythmias and mortality. [2008.09]
In vitro-in vivo correlation for wet-milled tablet of poorly water-soluble cilostazol. [2008.08.25]
Cilostazol reduces restenosis after endovascular therapy in patients with femoropopliteal lesions. [2008.07]
|
